CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: CC chemokine receptor 4 (CCR4) is overexpressed in CTCL skin lesions at all stages of disease and is recognized as a promising novel therapeutic target for CTCL (Ferenczi, et al., 2002; Sugaya et al, 2015).